CRP and COVID-19: Diminished risk of severe COVID-19 in ARB-treated patients (Meng et al., 2020)Lower concentrations of CRP and procalcitonin in ACEi/ARB treated patients (Yang G. et al., 2020)≥ 20 registered clinical trials: CAPTOCOVID (NCT04355429), RAMIC (NCT04366050), NCT04345406 (capto/enalapril), NCT04355936 (telmisartan).